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Safety of Carrageenan in
Foods
A recent review of the toxicology of car-
rageenan by Tobacman (1) raised questions
about the safety of carageenan-containing
foods. Intact carageenan is a high molecular
weight hydrocolloid (molecular weight
1.5–20 × 106). One concern has focused
on the potential for degraded (low molecu-
lar weight) carageenan to be formed by acid
hydrolysis in the stomach and the possibili-
ty that this material could promote cancer
of the colon (1). Rats fed degraded car-
rageenan have been shown to develop col-
orectal tumors (2). Studies involving initia-
tion with the genotoxic carcinogen
azoxymethane, followed by quantitation of
the number of aberrant intestinal crypts
formed in response to subsequent car-
rageenan exposure, have also suggested that
degraded carageenan has the potential to
promote colon cancer in rats (3).
These findings have led to degraded
carrageenan being classified by the
International Agency for Research on
Cancer (IARC) as 2B, a possible human
carcinogen, based on animal study data.
Native carrageenan has been classified by
IARC as 3, unclassifiable with respect to
carcinogenicity in humans.
In a recent paper, Taché et al (4) used
a well-established and highly sensitive
aberrant crypt assay to examined the
potential for carrageenan to promote
azoxymethane-induced colonic cancer;
they found no promoting effect when a
humanized gut flora was used. Because the
carrageenan was administered in the drink-
ing water, it was available for degradation
in the acidic environment of the stomach.
The use of normal rodent microbiologic
flora produced a promoting effect of car-
rageenan in this model system (4), con-
firming positive results of previous studies,
in contrast with the negative effect that
occurred using humanized intestinal flora
in the rat. Thus, the conclusion must be
that this colon cancer-promoting effect is a
rodent-specific phenomenon, requiring a
rodent intestinal microbiologic flora, and
that carrageenan would not promote colon
cancer in humans.
The concerns with regard to the induc-
tion of ulcerative colitis expressed by
Tobacman (1) are also inappropriately
extrapolated from animal data with regard
to human risk. There have been many
studies carried out with carrageenan in ani-
mals, and carrageenan has been used to
induce inflammation in susceptible species
and to test the anti-inflammatory proper-
ties of new candidate drugs. Although
guinea pigs are very sensitive to the induc-
tion of colitis by carrageenan, primates—a
more appropriate species for comparison to
humans—are resistant to the induction of
colitis by carrageenan.
The safety of carrageenan for use in foods
was confirmed at the 57th meeting of the
Joint Food and Agriculture Organization 
of the United Nations/World Health
Organization Expert Committee on Food
Additives (JECFA) in Rome in June 2001
(5). The JECFA recommended an acceptable
daily intake (ADI) of “not specified,” the
most favorable ADI for a food additive. This
recommendation was made after a review of
all of the current toxicology and carcino-
genicity studies on carrageenan by two world
experts in this field, S. Cohen (University of
Nebraska Medical Center, Omaha, NE,
USA) and N. Ito (Nagoya City University
Medical School, Nagoya, Japan). It included
consideration of studies not cited by
Tobacman (1) in her evaluation.
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Carrageenan in Foods:
Response
Carrageenan has been the subject of signifi-
cant investigation for several decades, and
the complexity pertaining to it may have
impeded our ability to form a clear impres-
sion about its harmful effects. In rodent
models, there is clear evidence that degrad-
ed carrageenan can induce ulcerations and
neoplasms. Also, there is clear evidence that
food-grade carrageenan can be broken
down to degraded carrageenan by acid
hydrolysis and by bacteria, and degraded
carrageenan is likely to contaminate food-
grade carrageenan. Although most of our
concerns about carcinogenic exposures arise
in relation to the unmetabolized product,
the situation with carrageenan requires
some extension of our perspective to recog-
nize that exposure to undegraded car-
rageenan is inevitably accompanied by
exposure to degraded carrageenan. If we
accept the Delaney standard of no known
carcinogens in food or the pesticide stan-
dard of no more than one in part in a mil-
lion (1), the use of carrageenan in food is
clearly in excess.
Carthew has raised issues pertaining to
the role of human intestinal flora on the
effects related to carrageenan and the possi-
bility of interspecies variation in the toxicity
of carrageenan. The paper by Taché et al.
(2) referred to by Carthew actually supports
concerns about the availability of degraded
carrageenan after exposure to food-grade
carrageenan and human microflora. The
authors report data on the average molecu-
lar weight of carrageenan recovered from
stool samples in feeding experiments with
rats in which human intestinal microflora
had been introduced. The average molecu-
lar weight of the carrageenan extracted from
feces was 346,000 ± 18,000 in the rats with
the conventional intestinal flora and was
slightly lower (307,000 ± 37,000) in the
rats exposed to human intestinal microflora.
This strongly suggests that metabolism of
dietary carrageenan does not depend on the
presence of rodent microflora. 
Interpretation of Taché et al.’s (2) data
on the number of crypt foci and the num-
bers of aberrant crypts is confounded by
lack of a comparable control group, as
noted by the authors. When they sought to
expose a control population to similar con-
ditions (life in an isolator, sawdust bed-
ding), they found that the rats developed
only 20 aberrant crypt foci per colon; this
was far less than the previously reported
controls that developed 86 ± 23 aberrant
crypt foci per colon or the experimental
animals with human intestinal microflora
that developed 55 ± 18 aberrant crypt foci
per colon (3), suggesting unresolved experi-
mental issues pertaining to initiation. This
confounds interpretation of the data about
promotion. Also, Taché et al. (2) did not
provide details about the actual composi-
tion of the microflora in their experimental
rats, and we do not know if it was consis-
tent throughout the experiment. Hence,
these data cannot be used to declare that
the colon cancer-promoting effect of food-
grade carrageenan is a “rodent-specific phe-
nomenon” and that it requires a rodent
intestinal microbiologic flora. 
When the Food and Drug Administration
(FDA) considered the status of carrageenan
in the early 1970s, their review included a
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ate controls (4,5). Investigators observed
that monkeys fed 2% degraded carrageenan
did not gain weight, had an immediate
change in stool consistency, and consistently
had blood in their stools, which was associ-
ated with a decline in hemoglobin, until
approximately 10 weeks after the withdraw-
al of the carrageenan. In addition, they
developed mucosal erosions and ulceration
and multiple crypt abscesses. Pathologic
changes were dose and duration dependent.
Thus, these data indicate that degraded car-
rageenan can induce colitis in primates. 
It is unfortunate that the June 2001
meeting of the FAO/WHO Expert
Committee on Food Additives (JECFA)
(6) rated the acceptable daily intake (ADI)
of carrageenan as “not specified,” as they
had done previously, including at the 28th
meeting in 1984 (7), rather than establish-
ing a different position. In the 1999 report
on carrageenan prepared as part of the
World Health Organization Food
Additives Series, Greig (8) stated that the
JECFA ADI of “not specified” for car-
rageenan was temporary, pending review in
2001. Also, Greig (8) pointed out that
degraded carrageenans and processed
Eucheuma seaweed were not included by
the JECFA in the specifications of food-
grade carrageenan in 1984. Subsequently, a
review of carrageenan was undertaken for
the 2001 meeting. Greig (8; p. 16) noted
that 
Maintenance of a restriction on the relative mass
distribution in the specifications of carrageenan
for food use provides protection against the
adverse effects of carageenans (sp) of low relative
molecular mass. 
However, in 2001 the JECFA apparently
did not endorse any specific restriction on
the molecular weight of food-grade car-
rageenan. The report of Cohen and Ito to
which Carthew refers and the full report of
JECFA 2001 are not yet published.
I hope that the recommendations per-
taining to carrageenan will be revised by
regulatory groups. Clearly, there are signifi-
cant economic issues and interests for the
food industry and for populations involved
in farming red seaweeds. In the United
States, the FDA has ignored the harmful
potential of carrageenan for over 20 years,
but now is the time to reevaluate car-
rageenan and its potential harmful effects. 
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Time for a Change in
Philosophy
As people are becoming aware, there are
signs that Earth is demonstrating finite
capabilities to support the continued exis-
tence of life. The atmosphere appears to be
heating, the oceans appear to be declining
in their ability to support life, and many
species of wildlife are becoming extinct. 
The prevailing thought in the social sci-
ences seems to be that the planet has infinite
capacity to support the continued existence
of life. All theology and all philosophy relat-
ed to governments and cultural habits were
developed on the basis of the belief that the
planet had infinite capacity to support life,
but this was ages ago, when the planet’s
resources truly appeared to be endless. 
The philosophies now being followed
largely determine how people judge right
from wrong and, although most people
may not realize it, motivate couples to have
large families. As a consequence, the world
population is growing exponentially larger.
The world population grows in number
similarly to the way bacteria grows under
favorable conditions. Every generation is
larger than the generation preceding it. 
Without a major change in the philoso-
phies of the world population, which moti-
vate people as a whole to behave very
destructively toward their own survival inter-
ests, life on this planet will have a limited
future. 
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Mercury and the Central
Nervous System 
The toxicity of mercury described in the
table in “Environmental Aftermath” (1) in
EHP [109:A530 (2001)] needs clarification.
In the table, mercury is cited as damag-
ing only the peripheral nervous system. Of
much greater public health concern, how-
ever, are the toxic effects of mercury to the
central nervous system (CNS). Organic
mercurials, particularly methyl mercury,
preferentially accumulate within cerebellar
neurons of the CNS and, in significant
concentrations, can thereby affect motor
function and coordination, particularly in
the fetus. Elemental mercury, the form
found in thermometers and precision
instruments, as cited in the table, is prefer-
entially distributed as mercury vapor to
centers of the CNS that affect cognitive
function (personality and behavior) rather
than those that control motor function.
These are the effects of predominant public
health concern associated with mercury
exposure from environmental sources. This
clarification may be of interest to those
concerned about mercury exposure associ-
ated with the World Trade Center site. 
James S. Woods
School of Public Health and 
Community Medicine
University of Washington
Seattle, Washington 
E-mail: jwoods@u.washington.edu
REFERENCES AND NOTES
1. Claudio L. Environmental aftermath. Environ Health
Perspect 109:529–536 (2001).
Environmental Health Perspectives • VOLUME 110 | NUMBER 4 | April 2002 A 177
Correspondence